Dendreon Company Profile (NASDAQ:DNDN)

About Dendreon (NASDAQ:DNDN)

Dendreon logoDendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DNDN
  • CUSIP: 24823Q10
  • Web: www.dendreon.com/
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.32
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -30.18%
  • Return on Assets: -25.12%
 
Frequently Asked Questions for Dendreon (NASDAQ:DNDN)

What is Dendreon's stock symbol?

Dendreon trades on the NASDAQ under the ticker symbol "DNDN."

How were Dendreon's earnings last quarter?

Dendreon Co. (NASDAQ:DNDN) released its quarterly earnings data on Monday, November, 10th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The business earned $73.10 million during the quarter, compared to analyst estimates of $78.72 million. The business's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) EPS. View Dendreon's Earnings History.

Who are some of Dendreon's key competitors?

How do I buy Dendreon stock?

Shares of Dendreon can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dendreon's stock price today?

One share of Dendreon stock can currently be purchased for approximately $0.13.


MarketBeat Community Rating for Dendreon (NASDAQ DNDN)
Community Ranking:  1.0 out of 5 ()
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Dendreon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dendreon (NASDAQ:DNDN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Dendreon (NASDAQ:DNDN)
Earnings by Quarter for Dendreon (NASDAQ:DNDN)
Earnings History by Quarter for Dendreon (NASDAQ DNDN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2014Q3($0.10)($0.14)$78.72 million$73.10 millionViewN/AView Earnings Details
8/20/2014($0.18)($0.18)ViewN/AView Earnings Details
8/11/2014($0.25)($0.10)$73.37 million$82.16 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.24)$69.19 million$68.70 millionViewListenView Earnings Details
3/3/2014Q413($0.37)($0.17)$73.59 million$74.80 millionViewListenView Earnings Details
11/12/2013Q313($0.42)($0.44)$76.60 million$68.00 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.42)($0.45)$75.61 million$73.30 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.47)($0.48)$80.15 million$67.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.56)($0.26)$82.88 million$85.49 millionViewN/AView Earnings Details
11/2/2012Q312($0.75)($0.33)$80.68 million$78.00 millionViewN/AView Earnings Details
5/2/2011($0.70)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dendreon (NASDAQ:DNDN)
Current Year EPS Consensus Estimate: $-0.730 EPS
Next Year EPS Consensus Estimate: $-0.400 EPS

Dividends

Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Dendreon (NASDAQ:DNDN)
Latest Headlines for Dendreon (NASDAQ:DNDN)
Source:
DateHeadline
seekingalpha.com logoValeant completes Dendreon sale to Sanpower for ~$820M; Cantor bullish, boosts price target to $23; shares ahead 4% premarket
seekingalpha.com - June 29 at 7:49 AM
thestreet.com logoJim Cramer on L'Oreal's Deal for Valeant's Skin Care Lines - TheStreet.com
www.thestreet.com - January 10 at 12:48 PM
seekingalpha.com logoValeant sells Dendreon for $819.9M
seekingalpha.com - January 9 at 11:29 PM
bizjournals.com logoConsultant: 'There may be no profitable biotechs in Seattle,' and that's OK
www.bizjournals.com - September 7 at 4:47 PM
seekingalpha.com logoFDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarket - Seeking Alpha
seekingalpha.com - February 10 at 4:40 PM
seekingalpha.com logoAre MannKind's Lenders Calling The Shots? - Seeking Alpha
seekingalpha.com - January 19 at 4:03 PM
finance.yahoo.com logoMy Favorite Under $5 Biotech Could Soar 150% or More
finance.yahoo.com - May 6 at 8:08 AM
finance.yahoo.com logoThe First Rule of Short Selling Is: Don’t Talk About Short Selling
finance.yahoo.com - March 12 at 11:39 PM
bloomberg.com logoDendreon’s Enhanced $445 Million Sale to Valeant Approved
www.bloomberg.com - February 20 at 2:06 PM
finance.yahoo.com logoValeant to buy bankrupt vaccine maker Dendreon
finance.yahoo.com - February 10 at 5:51 PM
bloomberg.com logoDendreon’s Price Jumps 35% Before Bankruptcy Auction Even Starts
www.bloomberg.com - February 5 at 1:19 PM
thestreet.com logoDendreon's Asset Rummage Sale Completes the Circle of Life
www.thestreet.com - January 30 at 6:01 AM
finance.yahoo.com logoValeant to buy Dendreon's prostate cancer vaccine Provenge
finance.yahoo.com - January 29 at 11:01 PM
finance.yahoo.com logoValeant to buy worldwide rights to Dendreon's Provenge
finance.yahoo.com - January 29 at 9:29 PM
finance.yahoo.com logoDendreon heads to auction without initial bidder
finance.yahoo.com - December 29 at 4:40 PM
finance.yahoo.com logoDendreon's Dead Enders Still Blaming Everyone But Themselves
finance.yahoo.com - November 10 at 2:11 PM
finance.yahoo.com logoDendreon files for Ch. 11 bankruptcy protection
finance.yahoo.com - November 10 at 1:31 PM
finance.yahoo.com logoUPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints
finance.yahoo.com - November 10 at 12:42 PM
247wallst.com logoThe Shame and Lessons of a Dendreon Bankruptcy
247wallst.com - November 10 at 8:15 AM
finance.yahoo.com logoDendreon files for Chapter 11 bankruptcy
finance.yahoo.com - November 10 at 2:22 AM
247wallst.com logoIs an Impending Implosion of Dendreon Avoidable?
247wallst.com - August 12 at 12:54 PM
seekingalpha.com logoApple And Others Should Issue Debt Now
seekingalpha.com - January 27 at 12:18 AM

Social

Chart

Dendreon (DNDN) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff